

# Mapping the in vivo fitness landscape of lung adenocarcinoma tumor suppression in mice

Zoë N. Rogers<sup>1,8</sup>, Christopher D. McFarland<sup>2,8</sup>, Ian P. Winters<sup>1</sup>, Jose A. Seoane<sup>1,3,4</sup>, Jennifer J. Brady<sup>1</sup>, Stephanie Yoon<sup>5</sup>, Christina Curtis<sup>1,3,4,6</sup>, Dmitri A. Petrov<sup>1,2\*</sup> and Monte M. Winslow<sup>1,4,6,7\*</sup>

**The functional impact of most genomic alterations found in cancer, alone or in combination, remains largely unknown. Here we integrate tumor barcoding, CRISPR/Cas9-mediated genome editing and ultra-deep barcode sequencing to interrogate pairwise combinations of tumor suppressor alterations in autochthonous mouse models of human lung adenocarcinoma. We map the tumor suppressive effects of 31 common lung adenocarcinoma genotypes and identify a landscape of context dependence and differential effect strengths.**

Cancer growth is largely the consequence of multiple, cooperative genomic alterations<sup>1–3</sup>. Cancer genome sequencing has catalogued many of these alterations; however, the combinatorial effects of these alterations on tumor growth is largely unknown<sup>1,4</sup>. Most putative drivers are altered in less than 10% of tumors<sup>2</sup>, suggesting that these alterations may be inert, weakly beneficial, or beneficial only in certain genomic contexts. Inferring genetic interactions through co-occurrence rates alone is practically impossible, as the number of possible combinations scales factorially with candidate gene number. Genetically engineered mouse models can provide insight into gene function in tumors growing in an autochthonous setting; however, practical considerations have prevented broad studies of combinatorial tumor suppressor gene inactivation (Supplementary Fig. 1a)<sup>5,6</sup>. Hence our understanding of the genetic interactions that drive tumor growth in vivo remains limited.

To address these practical challenges, we recently developed a method to quantitatively measure the effect of many different tumor suppressor gene alterations in parallel using tumor barcoding coupled with high-throughput barcode sequencing (Tuba-seq)<sup>7</sup>. Tuba-seq combines genetically engineered mouse models of lung adenocarcinoma with CRISPR/Cas9-mediated tumor suppressor inactivation, tumor barcoding and deep sequencing of DNA barcodes. Because Tuba-seq measures the size of every tumor and is compatible with multiplexing tumor genotypes in individual mice, growth effects can be measured with unprecedented precision, sensitivity and throughput<sup>7</sup>. Here we employ this approach to systematically analyze pairwise combinations of tumor suppressor alterations in vivo. We quantified the growth of oncogenic *Kras*<sup>G12D</sup>-driven lung tumors with 31 common tumor suppressor genotypes (Supplementary Fig. 1a). We identified unexpected genetic interactions, found that the effects of most tumor suppressors are context-dependent, and explain several patterns of genetic alterations in human lung adenocarcinoma.


The tumor suppressor *TP53* is inactivated in more than half of human lung adenocarcinomas<sup>1, 4</sup>. To determine the effect of *Trp53* (*p53*) deletion on the growth suppressive effects of ten other putative tumor suppressors, we initiated tumors in *Kras*<sup>LSL-G12D</sup>; *Rosa26*<sup>LSL-tdTomato</sup>; *H11*<sup>LSL-Cas9</sup> (*KT;Cas9*) and *KT; Trp53*<sup>flox/flox</sup>; *Cas9* (*KPT;Cas9*) mice using a pool of barcoded Lenti-sgRNA/Cre vectors targeting many common tumor suppressor genes and four barcoded Lenti-sgInert/Cre vectors (Lenti-sgTS-Pool/Cre; Fig. 1, Supplementary Figs. 1 and 2, and Supplementary Tables 1 and 2)<sup>7</sup>. The barcodes in the Lenti-sgRNA/Cre vectors contain two components, which uniquely identify each tumor and its sgRNA, respectively (sgID-BC; Supplementary Fig. 2b)<sup>7</sup>. Thus, the number of neoplastic cells in each tumor of each genotype can be determined using our Tuba-seq approach: amplification of the sgID-BC region from bulk tumor-bearing lung genomic DNA, deep sequencing of the product, and tallying of each barcode using our analysis pipeline<sup>7</sup>. Using this approach, tumor sizes were determined 15 weeks after tumor initiation, when the lungs contained widespread hyperplasias, adenomas and some early adenocarcinomas<sup>7</sup>.

Tuba-seq analysis of *KT;Cas9* and *KPT;Cas9* mice uncovered an altered spectrum of tumor suppressive effects for many of the genes in our survey (Fig. 1 and Supplementary Fig. 3). Tumor sizes were summarized by two previously vetted measures: log-normal (LN) mean and the size of the 95th percentile tumor (Fig. 1c,d and Methods)<sup>7</sup>. In *Trp53*-deficient tumors, inactivation of *Rb1*, *Setd2*, *Lkb1* (*Stk11*), *Cdkn2a* or *Apc* still provided a growth advantage while *Smad4*, *Arid1a* and *Atm* emerged as tumor suppressors only in the absence of *Trp53* (Fig. 1b–e and Supplementary Fig. 3). The emergence of additional tumor suppressors in this background suggests that *Trp53* deficiency potentiates subsequent tumor evolution<sup>8</sup>. By enabling more mutations to be adaptive, *Trp53* loss may decrease the predictability of tumor evolution<sup>9</sup> and facilitate subsequent evolution, including the emergence of treatment resistance and metastatic disease<sup>10,11</sup>.

Coincident deletion of *Trp53* not only enabled more alterations to be adaptive, but also significantly changed the magnitude of effect of tumor suppressor loss. In *KT;Cas9* mice, *Rb1* deficiency increased tumor size less than *Lkb1* or *Setd2* deficiency (Fig. 1b–e and Supplementary Fig. 4a;  $P < 0.0001$  bootstrap test unless otherwise specified; Methods). In contrast, in the context of *Trp53* deficiency, *Rb1* deficiency conferred a growth advantage comparable to that of *Lkb1* or *Setd2* deficiency ( $P = 0.14$  and  $0.5$ , respectively), consistent with a strong complementary interaction between the *Trp53*

<sup>1</sup>Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA. <sup>2</sup>Department of Biology, Stanford University, Stanford, CA, USA.

<sup>3</sup>Department of Medicine (Oncology), Stanford University School of Medicine, Stanford, CA, USA. <sup>4</sup>Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA. <sup>5</sup>Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA. <sup>6</sup>Cancer Biology Program, Stanford University School of Medicine, Stanford, CA, USA. <sup>7</sup>Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA. <sup>8</sup>These authors contributed equally: Zoë N. Rogers, Christopher D. McFarland. \*e-mail: [dpetrov@stanford.edu](mailto:dpetrov@stanford.edu); [mwinslow@stanford.edu](mailto:mwinslow@stanford.edu)




**Fig. 1 | Trp53 deficiency alters the growth effects of tumor suppression in *Kras*<sup>G12D</sup>-driven lung tumors in vivo. **a**, Tuba-seq approach to study combinatorial tumor suppressor inactivation in vivo. Tumors were initiated with Lenti-sgTS-Pool/Cre (containing four inert sgRNA vectors and eleven vectors targeting known and candidate tumor suppressor genes) in three different genetically engineered mouse backgrounds: *Kras*<sup>LSL-G12D/+</sup>; *Rosa26*<sup>LSL-tdTomato</sup>; *H1hLSL-Cas9* (*KT;Cas9*), *KT*; *Trp53*<sup>flax/flax</sup>; *Cas9* (*KPT;Cas9*) and *KT*; *Lkb1*<sup>flax/flax</sup>; *Cas9* (*KLT;Cas9*). Each sgRNA vector contains a unique sgID and a random barcode, which was used to quantify individual tumor sizes via deep sequencing. **b**, Analysis of relative tumor sizes in *KT;Cas9* mice 15 weeks after tumor initiation. Relative size of tumors at the indicated percentiles is merged data from 10 mice, normalized to the average size of sgInert tumors. Error bars throughout this study denote 95% confidence intervals determined by bootstrap sampling. Percentiles that are significantly different from sgInert are in color. **c**, Estimates of mean tumor size, assuming a log-normal tumor size distribution, identified sgRNAs that significantly increased growth in *KT;Cas9* mice. Bonferroni-corrected, bootstrapped *P*-values are shown. sgRNAs with *P* < 0.05 are bold. **d, e**, Same as **b, c**, except for merged data from 12 *KPT;Cas9* mice. **f**, Abundance of indels at targeted loci relative to median of genome-targeting inert sgRNAs Neo1–Neo3. Coloring according to **a**. **g**, Functional mutations in *TP53* and *RB1* in human lung adenocarcinomas from TCGA and GENIE datasets (see URLs; *N* = 1,792). *RB1* and *TP53* alterations co-occur, as predicted from Tuba-seq fitness measurements. WT, wild type; Mut, mutated.**

and *Rb1* tumor suppressor pathways (Fig. 1d,e)<sup>12</sup>. Quantification of *Cas9*-generated indels at each targeted locus in bulk *KPT;Cas9* lung DNA identified comparably high percentages of *Lkb1*, *Setd2* and *Rb1* alleles with indels (Fig. 1f and Supplementary Fig. 5). Finally, we confirmed the effect of coincident inactivation of *Trp53* and *Rb1* on lung cancer growth using conventional *Cre/loxP*-based mouse models (Supplementary Fig. 4b–d).

The quantitatively different growth benefits of *Rb1* inactivation in *Trp53*-proficient versus *Trp53*-deficient tumors presented the opportunity to investigate whether changes in the fitness strength of a driver alter the frequency of its alterations in human lung adenocarcinomas. Co-occurrence of *RB1* alterations (single nucleotide variants and copy number variants) and *TP53* alterations were indeed enriched in human lung adenocarcinoma (*P* = 0.03; Fig. 1h and Supplementary Fig. 4e,f)<sup>14</sup>. Notably, despite a ~5-fold enrichment in the co-occurrence of these two alterations, this interaction would be statistically insignificant in a naive survey of all potential pairwise driver interactions after correcting for multiple-hypothesis testing, thus illustrating the need to study genetic interactions beyond co-occurrence patterns (*P* = 0.32 after Bonferroni correction for 10 pairwise interactions)<sup>13</sup>.

Next we investigated the effects of combinatorial loss of *Lkb1* and other putative tumor suppressors by initiating tumors with Lenti-sgTS-Pool/Cre in *KT*; *Lkb1*<sup>flax/flax</sup>; *Cas9* (*KLT;Cas9*) mice (Fig. 2a,b and Supplementary Fig. 3g–i). We investigated *Lkb1* because it is frequently inactivated in human lung adenocarcinoma<sup>4</sup> and because *Lkb1* loss dramatically increases lung tumor growth in autochthonous models<sup>7,14</sup> (Supplementary Fig. 1b). Notably, both the number of adaptive tumor suppressor losses and the median growth benefit was attenuated in the already fast-growing *Lkb1*-deficient tumors (irrespective of changes in statistical power between mouse backgrounds; *P* < 0.05, Methods). This once again demonstrates that a single alteration can dramatically change the fitness landscape of tumors. The general attenuation of fitness benefits as additional growth-promoting alterations are acquired, termed diminishing returns epistasis, is common in evolution<sup>15,16</sup> and suggests that tumors may eventually reach a fitness plateau.

*Apc* and *Rb1* inactivation were the only alterations that provided a significant growth advantage to *Lkb1*-deficient tumors (Fig. 2a,b). The ability of *Rb1* deficiency to increase tumor size, even with coincident *Lkb1* deficiency, emphasizes the integral role of *Rb1* in cell cycle regulation<sup>12,17</sup> and fundamentally different



**Fig. 2 | Attenuated effects of tumor suppressor inactivation in *Lkb1*-deficient tumors further highlights a rugged fitness landscape.** **a**, Tumor sizes at indicated percentiles for each sgRNA relative to the average of sgInert-containing tumors at the same percentiles. Merged data from 13 *KT;Lkb1<sup>fllox/fllox</sup>;Cas9* (*KLT;Cas9*) mice 15 weeks after tumor initiation with Lenti-sgTS-Pool/Cre. Percentiles significantly different from sgInert are in color. Error bars denote 95% confidence intervals determined by bootstrap sampling. **b**, Estimates of mean tumor size, assuming a log-normal tumor size distribution, identified sgRNAs that significantly increase growth in *KLT;Cas9* mice. Bonferroni-corrected, bootstrapped *P*-values are shown. *P* < 0.05 indicated by bold. **c**, Mutual exclusivity of *STK11* (*LKB1*) and *SETD2* mutations in human lung adenocarcinomas from TCGA and GENIE datasets (*N* = 1,792). WT, wild type; Mut, mutated. **d**, Tumor sizes in *KPT;Cas9* mice with Lenti-sgSetd2/Cre-initiated tumors (*N* = 7) versus *KPT;Cas9* mice with Lenti-sgNeo2/Cre-initiated tumors (*N* = 3). LN mean size is 2.4-fold greater in Lenti-sgSetd2/Cre-initiated tumors than Lenti-sgNeo2/Cre-initiated tumors and the 95th percentile of tumor size is 4.6-fold greater. **e**, Tumor sizes in *KLT;Cas9* mice with Lenti-sgSetd2/Cre-initiated tumors (*N* = 7) versus *KLT;Cas9* mice with Lenti-sgNeo2/Cre-initiated tumors (*N* = 5). Relative LN mean and relative 95th percentile are both significantly less than in Fig. 2d (*P* = 0.04 and *P* < 0.0001, respectively). **f**, Pearson correlations of fitness effect of tumor suppressors (determined by LN mean) across genetic backgrounds. sgTrp53 and sgLkb1 growth rates are excluded in *KPT;Cas9* and *KLT;Cas9* mice, respectively. \**P* = 0.04, \*\*\*\**P* < 0.0001. **g**, Differential effect of each tumor suppressor gene with coincident *Trp53* or *Lkb1* deficiency. 95th percentiles that significantly deviate from sgInert tumors are in blue. **h**, Likelihood of identifying candidate tumor suppressors as drivers (as defined in **g**) versus the number of contexts studied. All possible genetic contexts were averaged.

mechanism of action from *Lkb1*<sup>18</sup>. *Apc* loss is also a key driver of lung cancer growth<sup>7,19</sup>, and *Apc* was tumor suppressive in all three backgrounds studied.

Surprisingly, the effect of *Setd2* deficiency on the growth of *Lkb1*-deficient tumors was modest and not statistically significant (Fig. 2a,b). This redundancy is striking because both *Lkb1* and *Setd2* inactivation strongly promote growth in *KT;Cas9* and *KPT;Cas9* mice and because there is no evidence that these genes function in the same pathway<sup>7,20</sup>. We tested and confirmed the context dependence of *Setd2* inactivation by initiating tumors with Lenti-sgNeo2/Cre and Lenti-sgSetd2/Cre in *KPT*, *KPT;Cas9* and *KLT;Cas9* mice. *Setd2* inactivation enhanced *Lkb1*-proficient lung tumor growth while conferring little, if any, growth advantage on *Lkb1*-deficient tumors (Fig. 2d,e and Supplementary Fig. 6). This observation is also well supported by the mutual exclusivity of *LKB1* and *SETD2* alterations in human lung adenocarcinoma (*P* < 0.001, Fig. 2c and Supplementary Fig. 6).

Most genes in our study exhibited context-dependent growth effects, driving tumor growth only in the presence or absence of

*Trp53* or *Lkb1* (Fig. 2f,g). Even the tumor suppressor alterations that conferred advantage in all three contexts (*Rb1* and *Apc*) still exhibited context-dependent magnitudes of tumor suppression. Such widespread context dependency is overlooked by global surveys of drivers, where driver interactions are either ignored<sup>1,2</sup> or presumed to be sufficiently rare and/or weak to justify considering only marginal correlations<sup>3,13</sup>. Nonetheless, our fitness measurements generally agree with mutation co-occurrence patterns in human lung cancer, despite the limited statistical resolution of these data (Spearman *R* = 0.50, *P* = 0.03, Supplementary Fig. 7)<sup>14</sup>. Furthermore, lung cancers do not appear to be unique in their degree of context dependency (Supplementary Fig. 7c), suggesting that direct measurement of context dependency in other cancer types is warranted.

This rugged landscape of tumor evolution has several implications. First, to understand gene function, it is necessary to investigate putative drivers in multiple genetic contexts, as most genes in our survey (8 of 11) were adaptive in only some contexts (Fig. 2h). Second, broader fitness profiling is needed. Power analyses suggest

that ~500 moderate-strength interactions could be surveyed using Tuba-seq in a 100-mouse cohort (Supplementary Fig. 8). Larger genomic screens could survey more putative drivers, interactions with other oncogenic events, or triplets of tumor suppressor alterations. Lastly, this extensive context dependency suggests that most driver alterations sweep to fixation infrequently because they are beneficial only in specific genetic contexts.

Our study of the fitness effects of combinatorial tumor suppressor losses *in vivo* has identified unexpected genetic interactions that were validated by traditional methodologies, as well as by human lung adenocarcinoma genomics data. Our barcoded and multiplexed *in vivo* genome-editing approach could be easily employed to interrogate these genetic interactions' impacts on therapeutic response, cell signaling or metastatic progression.

## Methods

Methods, including statements of data availability and any associated accession codes and references, are available at <https://doi.org/10.1038/s41588-018-0083-2>.

Received: 30 August 2017; Accepted: 2 February 2018;

Published online: 02 April 2018

## References

1. Cancer Genome Atlas Research Network. *Nature* **511**, 543–550 (2014).
2. Lawrence, M. S. et al. *Nature* **505**, 495–501 (2014).
3. Mina, M. et al. *Cancer Cell* **32**, 155–168.e6 (2017).
4. AACR Project GENIE Consortium. *Cancer Discov.* **7**, 818–831 (2017).
5. Kersten, K., de Visser, K. E., van Miltenburg, M. H. & Jonkers, J. *EMBO Mol. Med.* **9**, 137–153 (2017).
6. Frese, K. K. & Tuveson, D. A. *Nat. Rev. Cancer* **7**, 645–658 (2007).
7. Rogers, Z. N. et al. *Nat. Methods* **14**, 737–742 (2017).
8. Lenski, R. E. et al. *Proc. Biol. Sci.* **282**, 20152292 (2015).
9. de Visser, J. A. G. M. & Krug, J. *Nat. Rev. Genet.* **15**, 480–490 (2014).
10. Siegal, M. L. & Leu, J. *Annu. Rev. Ecol. Evol. Syst.* **45**, 496–517 (2014).
11. Keshelava, N. et al. *Cancer Res.* **61**, 6185–6193 (2001).
12. Sherr, C. J. & McCormick, F. *Cancer Cell* **2**, 103–112 (2002).
13. Canisius, S., Martens, J. W. M. & Wessels, L. F. A. *Genome Biol.* **17**, 261 (2016).
14. Ji, H. et al. *Nature* **448**, 807–810 (2007).
15. Chou, H.-H., Chiu, H.-C., Delaney, N. F., Segrè, D. & Marx, C. J. *Science* **332**, 1190–1192 (2011).
16. Wünsche, A. et al. *Nat. Ecol. Evol.* **1**, 61 (2017).
17. Burkhart, D. L. & Sage, J. *Nat. Rev. Cancer* **8**, 671–682 (2008).
18. Hardie, D. G. & Alessi, D. R. *BMC Biol.* **11**, 36–47 (2013).
19. Sánchez-Rivera, F. J. et al. *Nature* **516**, 428–431 (2014).
20. Walter, D. M. et al. *Cancer Res.* **77**, 1719–1729 (2017).

## Acknowledgements

We thank P. Chu and R. Ma for technical support, A. Orantes for administrative support, members of the Petrov and Winslow laboratories for comments, and T. Jacks for initial support. Z.N.R. and I.P.W. were supported by the National Science Foundation Graduate Research Fellowship Program (GRFP). Z.N.R. was additionally supported by a Stanford Graduate Fellowship. I.P.W. was additionally supported by NIH F31CA210627 and NIH T32HG000044. C.D.M. was supported by NIH E25CA180993. J.J.B. was supported by NIH F32CA189659. J.A.S. was supported by Susan G. Komen for the Cure PDF16377256. D.P. is the Michelle and Kevin Douglas Professor of Biology. This work was supported by NIH R01CA175336 (to M.M.W.), R01CA207133 (to D.P. and M.M.W.), and in part by the Stanford Cancer Institute support grant (NIH P30CA124435). The authors would like to acknowledge the American Association for Cancer Research and its financial and material support in the development of the AACR Project GENIE registry, as well as members of the consortium for their commitment to data sharing. Interpretations are the responsibility of study authors.

## Author contributions

Z.N.R. generated barcoded vectors, produced lentivirus and performed mouse analysis, indel analysis and analysis of single sgRNA tumor sizes. C.D.M. performed data analysis, including processing sequencing data, and all statistical analyses. I.P.W. generated the mouse models, selected tumor suppressors to investigate, designed sgRNAs, generated Lenti-sgRNA/Cre vectors, tested sgRNA cutting efficiency, produced lentivirus and performed indel analysis. J.A.S. and C.C. performed analysis of human cancer datasets. S.Y. and J.J.B. contributed to experiments and analyses. D.A.P. and M.M.W. oversaw the project. Z.N.R., C.D.M., D.A.P. and M.M.W. wrote the manuscript with comments from all authors.

## Competing interests

Stanford University has filed a patent (US Provisional Application 62/481,067) based on this work in which Z.N.R., I.P.W., C.M., D.A.P., and M.M.W. are coinventors.

## Additional information

**Supplementary information** is available for this paper at <https://doi.org/10.1038/s41588-018-0083-2>.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Correspondence and requests for materials** should be addressed to D.A.P. or M.M.W.

**Publisher's note**: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## Methods

**Mice and tumor initiation.** *Kras<sup>LSL-G12D</sup> (K)*, *Lkb1<sup>fllox</sup> (L)*, *Trp53<sup>fllox</sup> (P)*, *R26<sup>LSL-Tomato</sup> (T)*, *H11<sup>LSL-Cas9</sup> (Cas9)* and *Rb1<sup>fllox</sup>* mice have been described<sup>21–26</sup>. Lung tumors were initiated by intratracheal transduction of mice as previously described<sup>27</sup> using lentiviral-Cre vectors at indicated titers. Tumor burden was assessed by fluorescence microscopy and histology where indicated. All experiments were performed in accordance with Stanford University Institutional Animal Care and Use Committee guidelines.

**Lentiviral titers and time of analysis.** Lentiviral titers administered to *KT;Cas9*, *KPT;Cas9* and *KLT;Cas9* mice were  $22 \times 10^3$ ,  $9 \times 10^3$  and  $4.5 \times 10^3$  infectious particles per mouse, respectively. These titers were chosen to approximately balance total tumor burden across the mice at the time of analysis at 15 weeks after tumor initiation (i.e. backgrounds with faster-growing tumors on average received lower titers). Anticipated growth rates were determined previously<sup>7</sup>. 15 weeks was chosen because tumors grown for 15 weeks in *KT;Cas9* mice exhibited easily resolved differences in tumor size (by both Tuba-seq and histological analysis)<sup>7</sup>.

**Generation of the barcoded Lenti-sgTS-Pool/Cre vector pool.** To enable quantification of the number of cancer cells in individual tumors in parallel using high-throughput sequencing, we diversified lentiviral-sgRNA/Cre vectors with a short barcode sequence that contains a sequence unique to each sgRNA (sgID) and a sequence unique to each tumor (BC). Cancer cells in individual tumors contain a lentiviral vector that stably integrated into the genome of the initial transduced lung epithelial cell<sup>7</sup>. We generated tumors using a pool of 15 barcoded Lenti-U6-sgRNA/PGK-Cre vectors in three different genetic backgrounds by initiating tumors in three different genotypes of mice: *KT; H11<sup>LSL-Cas9/LSL-Cas9</sup> (KT;Cas9)*, *KPT; H11<sup>LSL-Cas9/LSL-Cas9</sup> (KPT;Cas9)* and *KT; Lkb1<sup>fllox/fllox</sup>; H11<sup>LSL-Cas9/LSL-Cas9</sup> (KLT;Cas9)*. The design and barcoding of these lentiviral sgRNA/Cre vectors was previously described<sup>7</sup>. We pooled barcoded Lenti-sgRNA-sgID-BC/Cre vectors (sgLkb1, sgTrp53, sgApc, sgAtm, sgArid1a, sgCdkn2a, sgKeap1, sgNeo1, sgNeo2, sgNeo3, sgNT1, sgRb1, sgRbm10, sgSetd2 and sgSmad4) to generate Lenti-sgTS-Pool/Cre, as previously described<sup>7</sup>. A detailed protocol for barcoding lentiviral vectors can be found on Protocol Exchange<sup>28</sup>.

**Production, purification and titering of lentivirus.** Lentiviral vectors were produced using polyethylenimine-based transfection of 293 T cells with the lentiviral vectors and delta.8.2 and VSV-G packaging plasmids. Lenti-sgTS-Pool/Cre, Lenti-sgSetd2/Cre and Lenti-sgNeo2/Cre were generated for tumor initiation as described previously<sup>7</sup>. Concentrated lentiviral particles were titered by transducing LSL-YFP cells (a gift from A. Sweet-Cordero, UCSF), determining the percent YFP-positive cells by flow cytometry, and comparing the titer to a lentiviral preparation of known titer.

**Generation of benchmark cell lines.** Three barcoded Lenti-Cre vectors with the sgID TTCTGCCT and unique BC barcodes were used to generate benchmark cell lines that were added to each bulk lung sample at a known cell number to enable calculation of the cancer cell number within each tumor, as previously described<sup>7</sup>.

**Isolation of genomic DNA from mouse lungs and preparation of sgID-BC libraries.** Genomic DNA was isolated from bulk tumor-bearing lung tissue from each of the mice, and Illumina sequencing libraries were prepared as previously described<sup>7</sup>. Detailed protocols can be found on Protocol Exchange<sup>29</sup>.

**Identifying distinct sgRNAs and tumors via ultra-deep sequencing.** A pair of unique DNA barcodes distinctly identify each tumor. These barcodes were detected via next-generation sequencing on Illumina HiSeq (2500 or 4000) platforms. Reads were filtered for quality and congruence with the expected lentiviral sequences flanking the barcodes, trimmed, and sorted into tallies of unique sequences. These unique barcode sequences were then annotated as tumors using the Tuba-seq barcode clustering algorithm described previously<sup>7</sup> and publicly released (see URLs). GC-content amplification bias was then subtracted using a fourth-order polynomial fit to the residual relationship between barcode GC-content and tumor size (LN mean size of all barcodes with a particular GC content after the LN mean effect of each sgRNA in each mouse has been subtracted), as recommended previously<sup>7</sup>. Lastly, the absolute number of neoplastic cells in each tumor was determined by multiplying the number of barcode reads for each tumor by the cell number of the three benchmark controls (500,000 cells, added to each mouse lung before lysis and DNA isolation) divided by their mean barcode tallies, as described previously<sup>7</sup>.

**Statistical summary of tumor size distributions.** Tumor size distributions across mice were cut off at 500 cells, the current resolution limit of Tuba-seq. Tumor sizes were normalized by dividing absolute tumor size by the median sgInert tumor size within a given mouse. This controls for the observed variability in median tumor size between replicate mice. Relative tumor sizes were then aggregated across replicate mice to produce a final size distribution for each genotype. All of these steps, and their statistical rationale, were described previously<sup>7</sup>.

We use two previously vetted<sup>7</sup> metrics to represent the distribution of tumor sizes observed in our various experiments: the 95th percentile of the tumor size distribution and the maximum-likelihood estimate of the mean based on a log-normal distribution (LN mean). Two summary statistics were used because Tuba-seq has identified reproducible differences in the shape of the tumor size distribution generated by different tumor suppressor alterations<sup>7</sup>, therefore making it impossible to completely summarize growth effects with any single measure. Briefly, the 95th percentile represents the best non-parametric summary of tumor growth, avoids issues intrinsic to the inefficiency of Cas9-mediated generation of frameshift mutations and focuses on growth differences between larger tumors, which are likely more relevant to cancer morbidity than small hyperplasias. The LN mean estimate represents the best overall parametric summary of tumor growth based on maximum likelihood quality of fit of various common parametric distributions. All Tuba-seq findings discussed in the main text were confirmed by both the LN mean summary measure and the 95th percentile summary measure, thus reducing the likelihood that these findings represent spurious growth effects.

Change in sgID representation was also used to assess tumor suppressive effects in a manner independent of the Tuba-seq pipeline (Supplementary Fig. 3). sgID representation was determined by tallying the reads associated with each sgID within each mouse (1 nucleotide mismatch was permitted). Relative sgID representation was determined by dividing each tally by the average tally of inert sgIDs within each mouse. Change in representation of each sgID was determined by dividing relative sgID representation in *KT;Cas9*, *KPT;Cas9* and *KLT;Cas9* mice by the mean relative sgID representation of tumors in the *KT* mice (which lack Cas9 and therefore do not introduce null alleles at the sgRNA target sites) transduced with the same Lenti-sgTS-Pool/Cre pool and grown for 12 weeks. Tumor growth distributions in *KT* mice were generated previously<sup>7</sup>. *P*-values and confidence intervals were determined by bootstrapping individual mouse sgID tallies for 2 million permutations (described below).

Our previous analysis of variance on the various sources of noise and experimental error in Tuba-seq found that change in sgID representation has less statistical resolution compared to measures that incorporate the sizes of all individual tumors and consider the entire tumor size distribution (also evident in Supplementary Fig. 3). This analysis of variance also found that it was unnecessary to normalize tumor size distributions by their representation in the Lenti-sgTS-Pool/Cre pool, as Tuba-seq accurately measures tumor number (i.e., the representation of each sgTS within the pool need not be explicitly accounted for when performing Tuba-seq analysis because Tuba-seq automatically identifies greater pool representation by virtue of there being more tumors). Hence, only bulk measurements that do not implicitly infer titers—i.e., relative sgID representation (not percentiles nor LN mean)—were normalized by representation in the lentiviral pool, as determined by tumor growth data in *KT* mice.

**Statistical tests.** Unless otherwise specified, all *P*-values and 95% confidence intervals were determined using the bootstrap resampling method. Estimates of the sampling distribution of every reported statistic were determined by redrawing from all observed relative tumor sizes using the bootstrap method (sampling with replacement of equal size to the observed sample). 10,000 bootstrap samples were drawn for any *P*-value reported to a 0.05 false discovery rate (FDR), 200,000 bootstrap samples were drawn for any percentile statistic reported, and 2,000,000 bootstrap samples were drawn for all LN mean estimates. *P*-values below a 0.0001 FDR (after correcting for multiple-hypothesis testing using the Bonferroni method) were reported as  $< 0.0001$ , as anything smaller exceeds the statistical power of our bootstrapping approach.

**Power analyses.** We used power analyses for two purposes: first, to determine whether the changes we observed in growth effects of putative tumor suppressors across the *KT;Cas9*, *KPT;Cas9* and *KLT;Cas9* mouse backgrounds were simply the result of changes in statistical power between these three backgrounds, and second, to calculate the number of mice need to enable the analyze of different numbers of experimental sgRNAs with sufficient statistical resolution.

Because *KT;Cas9*, *KPT;Cas9* and *KLT;Cas9* mice received different titers of lentiviral vectors (to balance total tumor burden), we investigated the possibility that the differences in the numbers of tumors analyzed between these mice altered the statistical power sufficiently to cause the changes observed in tumor suppressor effect in each background. *KT;Cas9* mice were initiated with the highest titer and had the most tumors, while *KLT;Cas9* mice were initiated with the lowest titer and had the fewest tumors. Thus, we drew random samples of tumors from *KT;Cas9* mice of a quantity equal to the number of tumors in *KLT;Cas9* mice and compared the number of statistically significant interactions observed in these two, now equally sized, sets of tumors. This comparison was made via nested resampling: 2,000 random samples (with replacement) of tumors from *KT;Cas9* mice were drawn, and the statistically significant functional tumor suppressors (0.05 FDR increase in LN mean relative to sgInert values) were determined using a second, bootstrap resampling, of these random samples. sgLkb1 was excluded, as this guide cannot be adaptive in the *KLT;Cas9* background. Finally, a sampling distribution of the number of functional tumor suppressors was generated and compared to the number of functional tumor suppressors in the *KLT;Cas9* background (two, sgRb1 and sgApc). Despite this reduction in the statistical resolution of growth effects in

*KT;Cas9* mice, more functional tumor suppressors were identified in the *KT;Cas9* background than the *KLT;Cas9* background ( $P < 0.05$ ,  $N = 44,743$  tumors in both the *KLT;Cas9* and downsampled *KT;Cas9* mice cohorts, two-sided test).

To project the effects of using larger mouse cohorts and larger Lenti-sgTS/Cre pools on the likelihood of identifying (i) functional tumor suppressors and (ii) driver interactions, we performed an additional power analysis, wherein tumors were presumed to abide by LN size distributions with parameters identical to the maximum likelihood estimates (MLEs) of observed size distributions.

For the statistical significance of tumor suppression, we compared MLEs of both the log-transformed mean and s.d. of sgLkb1 (strong driver), sgRb1 (moderate driver) and sgCdkn2a (weak driver) to the MLEs of all sgInert tumors (null hypothesis). Because a LN distribution is normal after a log transformation, the statistical significance of hypothetical experiments were determined using a two-sided, unequal-variance Student's *t*-test based on these log-transformed MLEs of the mean and s.d. of the representative tumor size distributions. The number of degrees of freedom in these tests were determined by projecting the number of tumors that would arise in an experiment assuming that mice harbored the same number of tumors as were present in our *KT;Cas9* mice with the same fraction of tumors initiated with Lenti-sgInert/Cre vectors. Lastly, raw *P*-values were transformed into estimates of the family-wise error rate (FWER) using the Bonferroni correction.

For the statistical significance of driver interactions, we compared the MLEs of sgSetd2 (normalized to median sgInert) in *KLT;Cas9* mice relative to the normalized sgSetd2 size distribution in *KT;Cas9* mice (strong interaction), normalized sgRb1 size distribution in *KPT;Cas9* versus *KT;Cas9* mice (moderate interaction) and normalized sgRbm10 size distribution in *KT;Cas9* versus *KPT;Cas9* mice (very weak interaction). The number of tumors and FWER were determined as described in the above paragraph. Because the LN distribution is scale invariant, a Student's *t*-test of log-transformed statistics remains equally effective after normalizing sizes relative to median sgInert, provided that the degrees of freedom are reduced accordingly.

This approach was used to generate Supplementary Fig. 8. This power analysis concludes that much larger screens are possible (>500 putative tumor suppressors or interaction pairs) and that it is useful to study tumor suppressor effects in a variety of genetic backgrounds even when this comes at the expense of reduced sample size within each background.

**Analysis of indels at target sites.** To confirm CRISPR/Cas9-induced indel formation in vivo, the targeted region of each gene of interest was PCR-amplified from genomic DNA extracted from bulk lung samples using GoTaq Green polymerase (Promega M7123) and primer pairs that yield short amplicons amenable to paired-end sequencing as previously described<sup>7</sup>. For each of the 14 targeted regions, alignments to octamer 'anchor' sequences ~25 bp on either side of the targeted region were conducted using bowtie2. Reads were required to contain both anchors to be linked to a given region. The length of each fragment between the two anchors was then determined and deviations from the expected length were then defined as indel-containing reads. The percentage of reads with indels at each target site in each tumor suppressor was normalized to the median percentage of indels observed in each of the three sgNeo target sites.

**Quantification of tumor area and barcode sequencing of tumors induced with Lenti-sgSetd2/Cre and Lenti-sgNeo/Cre.** To confirm the observed redundancy of loss of *Setd2* with loss of *Lkb1*, we analyzed tumor growth with and without *Setd2* loss in the *KPT*, *KPT;Cas9* and *KLT;Cas9* mice using de-multiplexed vectors, a second sgRNA targeting *Setd2*, and traditional tumor size quantification. These changes are intended to test whether technical details about the vectors, sgRNA design, or quantification method would alter our conclusions about the presence of this genetic interaction. Lenti-sgSetd2/Cre and Lenti-sgNeo/Cre vectors were administered to *KPT*, *KPT;Cas9* and *KLT;Cas9* mice. Lenti-sgSetd2/Cre and Lenti-sgNeo/Cre at  $2 \times 10^4$  infectious units per mouse were used to initiate tumors in *KPT* and *KPT;Cas9* mice. Lenti-sgSetd2/Cre and Lenti-sgNeo/Cre at  $1 \times 10^4$  infectious units per mouse were used to initiate tumors in *KLT;Cas9* mice. Mice were analyzed after 9 weeks of tumor growth.

Four tumor-bearing lobes from each lung were fixed in 4% formalin and paraffin-embedded. Hematoxylin and eosin staining was performed using standard methods. Percent tumor area (tumor area divided by total lung area) was determined using ImageJ. The distribution of the number of cancer cells in the tumors in the remaining lung lobe from these mice was determined using Tuba-seq<sup>7</sup>.

**Confirmation of *Rb1*-mediated tumor suppression in *Trp53*-deficient background.** To test the quantitative increase in fitness of *Rb1* loss in the *Trp53*-deficient background that we observed using our multiplexed Tuba-seq protocol, we investigated the growth effects of *Rb1* loss in *Trp53*-deficient and *Trp53*-proficient backgrounds using conventional *Cre/loxP* mouse models. *Kras<sup>LSL-G12D/+</sup>*

(*K*) and *Kras<sup>LSL-G12D/+</sup>; Rb1<sup>lox/lox</sup>* (*K;Rb<sup>lox/lox</sup>*) mice were transduced with  $3 \times 10^7$  Adeno-CMV-Cre virus (University of Iowa Viral Vector Core). *Kras<sup>LSL-G12D/+</sup>; Trp53<sup>lox/lox</sup>* (*KP*) and *Kras<sup>LSL-G12D/+</sup>; Trp53<sup>lox/lox</sup>; Rb1<sup>lox/lox</sup>* (*KP;Rb<sup>lox/lox</sup>*) mice were transduced with  $5 \times 10^6$  Adeno-CMV-Cre. All mice were analyzed 12 weeks after tumor initiation. Tumor areas was determined by histology as described above.

**Micro-computed tomographic and histologic analyses.** Tumors were visualized by micro-computed tomography ( $\mu$ CT) as described<sup>30</sup>. Briefly, lungs were collected, perfused with PBS to remove blood, and inflated with 4% formalin. The lungs were then sequentially kept in formalin and 20% IsoVue370/PBS over 2 separate days. Before imaging, each lung was perfused with soybean oil. Lungs were scanned with an eXplore Locus microCT scanner (GE Healthcare) at 22  $\mu$ m resolution. Images were visualized and reconstructed using GE eXplore software.

**Fitness correlations with *KT;Cas9* background.** Fitness vectors for each mouse background (*KT;Cas9*, *KPT;Cas9*, *KLT;Cas9*) were determined using the relative LN mean estimates of growth for every tumor suppressor in our screen (excluding all inert sgRNAs). Pearson correlations with previously published *KT;Cas9* (12 week) mice and *KT* mice were also determined<sup>7</sup>. Fitness vectors based on the relative 95th percentile tumor sizes exhibited a highly similar correlation matrix. The sgTrp53 and sgLkb1 LN mean estimates were excluded when correlating to *KPT;Cas9* and *KLT;Cas9* mice, respectively, as these guide RNAs do not induce genetic changes in the respective backgrounds. 200,000 bootstrap samplings of relative tumor sizes (as described in "Statistical tests") were drawn to produce *P*-values describing the likelihood that two correlation coefficients are identical. As positive and negative controls, the fitness vectors for *KT;Cas9* (12 weeks) mice and *KT* (12 weeks) mice were determined from previous data<sup>7</sup>.

**Analysis of co-occurrence and mutual exclusivity from human data.** TCGA lung adenocarcinoma somatic mutation and copy number were downloaded from the NCI Genomic Data Commons website (see URLs) and AACR GENIE (Genomics Evidence Neoplasia Information Exchange) via Synapse (see URLs) from the subset "Lung Adenocarcinoma". Silent mutations were removed from both datasets. Deletions from TCGA datasets were called as described in Curtis et al.<sup>31</sup>. The DISCOVER statistical test was used to determine co-occurrence and mutual exclusivity<sup>13</sup>. A total of 230 samples (TCGA, 2014)<sup>1</sup> and 1,563 samples (GENIE, 2017)<sup>1</sup> were studied.

**URLs.** Code, <https://github.com/petrov-lab/tuba-seq>; Addgene, <https://www.addgene.org/>; Genomic Data Commons, <http://gdc.cancer.gov>; Synapse, <http://www.synapse.org/#!Synapse:syn7222066>.

**Life Sciences Reporting Summary.** Further information on experimental design is available in the Life Sciences Reporting Summary.

**Data availability.** All major components of this study have been made publicly available. Plasmids have been described previously<sup>7</sup> and are available on Addgene (see URLs). *H1<sup>LSL-Cas9</sup>* mice are available from Jackson Laboratories (Jax 027650, 028239, 026816, 027632) and combination of strains can be requested directly from our laboratory. Tuba-seq protocols, including lentiviral vector barcoding<sup>28</sup>, genomic DNA extraction and library preparation<sup>29</sup>, are available on Protocol Exchange.

The Tuba-seq pipeline has been publicly released (see URLs). The code used for this experiment has been archived, but is also under active open-source development for improved general use. Raw sequencing files and processed tumor calls from every mouse are available on GEO (GSE107716). Statistical analysis code used downstream of tumor calls was described previously<sup>7</sup> and outlined above. We encourage direct contact with the authors who designed protocols and software, as best practices will evolve over time.

## References

- Jackson, E. L. et al. *Genes Dev.* **15**, 3243–3248 (2001).
- Madisen, L. et al. *Nat. Neurosci.* **13**, 133–140 (2010).
- Jonkers, J. et al. *Nat. Genet.* **29**, 418–425 (2001).
- Nakada, D., Saunders, T. L. & Morrison, S. J. *Nature* **468**, 653–658 (2010).
- Chiou, S. H. et al. *Genes Dev.* **29**, 1576–1585 (2015).
- Sage, J., Miller, A. L., Pérez-Mancera, P. A., Wsocki, J. M. & Jacks, T. *Nature* **424**, 223–228 (2003).
- DuPage, M., Dooley, A. L. & Jacks, T. *Nat. Protoc.* **4**, 1064–1072 (2009).
- Rogers, Z. *Protoc. Exch.* <https://doi.org/10.1038/protex.2017.090> (2017).
- Rogers, Z. *Protoc. Exch.* <https://doi.org/10.1038/protex.2017.091> (2017).
- Caunt, M. et al. *Cancer Cell* **13**, 331–342 (2008).
- Curtis, C. et al. *Nature* **486**, 346–352 (2012).

## Life Sciences Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.

For further information on the points included in this form, see [Reporting Life Sciences Research](#). For further information on Nature Research policies, including our [data availability policy](#), see [Authors & Referees](#) and the [Editorial Policy Checklist](#).

Please do not complete any field with "not applicable" or n/a. Refer to the help text for what text to use if an item is not relevant to your study. For [final submission](#): please carefully check your responses for accuracy; you will not be able to make changes later.

### ▶ Experimental design

#### 1. Sample size

Describe how sample size was determined.

The sample size of mice and of tumors are reported. The number of mice in each group was based on our previous studies of KTC mice. Tumor numbers were determined using the Tuba-seq pipeline as described in the Methods and provided on-line: [github.com/petrov-lab/tuba-seq](https://github.com/petrov-lab/tuba-seq).

#### 2. Data exclusions

Describe any data exclusions.

No Data was excluded.

#### 3. Replication

Describe the measures taken to verify the reproducibility of the experimental findings.

The Lenti-sgPool tumor size distributions within KT;Cas9 mice were highly-reproducible ( $R^2 = 0.96$  of LN Mean estimates) between mice harboring tumors for 12 and 15 weeks. The RB1-TP53 and SETD2-STK11 interactions were tested using traditional methodologies and reproduced our Tuba-seq finding.

#### 4. Randomization

Describe how samples/organisms/participants were allocated into experimental groups.

Mice cohorts were selected to be approximately half males and half females. The selection of mice for this study was based on availability.

#### 5. Blinding

Describe whether the investigators were blinded to group allocation during data collection and/or analysis.

Our Tuba-seq methodology naturally blinds researchers to the attributes of tumors, as they are only identifiable by DNA barcodes. Investigators were by necessity not blind to mouse genotypes, but the analysis closely followed our previous pipeline.

Note: all in vivo studies must report how sample size was determined and whether blinding and randomization were used.

## 6. Statistical parameters

For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).

n/a Confirmed

- The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
- A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- A statement indicating how many times each experiment was replicated
- The statistical test(s) used and whether they are one- or two-sided  
*Only common tests should be described solely by name; describe more complex techniques in the Methods section.*
- A description of any assumptions or corrections, such as an adjustment for multiple comparisons
- Test values indicating whether an effect is present  
*Provide confidence intervals or give results of significance tests (e.g.  $P$  values) as exact values whenever appropriate and with effect sizes noted.*
- A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
- Clearly defined error bars in all relevant figure captions (with explicit mention of central tendency and variation)

See the web collection on [statistics for biologists](#) for further resources and guidance.

## ► Software

Policy information about [availability of computer code](#)

### 7. Software

Describe the software used to analyze the data in this study.

The analysis software is provided here: [github.com/petrov-lab/tuba-seq](https://github.com/petrov-lab/tuba-seq), and was described in a previous paper: DOI:10.1038/NMETH.4297.

For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). [Nature Methods guidance for providing algorithms and software for publication](#) provides further information on this topic.

## ► Materials and reagents

Policy information about [availability of materials](#)

### 8. Materials availability

Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a third party.

The mouse models are publicly-accessible via the Jackson Laboratory or directly from our lab. Plasmid libraries are accessible via addgene.

### 9. Antibodies

Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).

No antibodies were used.

### 10. Eukaryotic cell lines

a. State the source of each eukaryotic cell line used.

No cell lines were used.

b. Describe the method of cell line authentication used.

Describe the authentication procedures for each cell line used OR declare that none of the cell lines used have been authenticated OR state that no eukaryotic cell lines were used.

c. Report whether the cell lines were tested for mycoplasma contamination.

Confirm that all cell lines tested negative for mycoplasma contamination OR describe the results of the testing for mycoplasma contamination OR declare that the cell lines were not tested for mycoplasma contamination OR state that no eukaryotic cell lines were used.

d. If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by [ICLAC](#), provide a scientific rationale for their use.

Provide a rationale for the use of commonly misidentified cell lines OR state that no commonly misidentified cell lines were used.



## ► Animals and human research participants

---

Policy information about [studies involving animals](#); when reporting animal research, follow the [ARRIVE guidelines](#)

### 11. Description of research animals

Provide all relevant details on animals and/or animal-derived materials used in the study.

Mouse models were described previously or detailed in the Methods. The mice were on a mixed BL6/129 background. All experiments were performed in accordance with Stanford University Institutional Animal Care and Use Committee guidelines.

Policy information about [studies involving human research participants](#)

### 12. Description of human research participants

Describe the covariate-relevant population characteristics of the human research participants.

No human participants were used.